Exelixis posts mixed results for Cabometyx combo in early liver cancer patients, casting doubt on pivotal readout
Exelixis envisioned a first-line approval for its super-seller Cabometyx in liver cancer, but after an interim readout produced mixed results, that picture is now a bit murky. Despite failing a key primary endpoint, the company’s racing full speed ahead toward a final readout — and a potential label expansion.
Cabometyx and Tecentriq reduced the risk of disease progression or death in hepatocellular carcinoma (HCC) patients by 37% compared with sorafenib (p= 0.0012), Exelixis said Monday morning. However, it failed to achieve a statistically significant improvement in overall survival at the interim analysis, and the company says the probability of hitting the endpoint in time for the final analysis is low.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.